How big is Sonnet BioTherapeutics Holdings, Inc.?

As of Jun 18, Sonnet BioTherapeutics Holdings, Inc. has a market capitalization of 3.67 million, with net sales of 1.00 million and a net profit of -13.29 million over the latest four quarters. The company reported shareholder's funds of -0.49 million and total assets of 2.77 million as of Sep 24.

Market Cap: As of Jun 18, Sonnet BioTherapeutics Holdings, Inc. has a market capitalization of 3.67 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Sonnet BioTherapeutics reported net sales of 1.00 million and a net profit of -13.29 million.<BR><BR>Balance Sheet Snapshot: As of Sep 24, the company reported shareholder's funds of -0.49 million and total assets of 2.77 million.

What does Sonnet BioTherapeutics Holdings, Inc. do?

Sonnet BioTherapeutics Holdings, Inc. is an oncology-focused biotechnology company developing targeted biologic drugs. It has a market cap of $3.67 million and reported a net profit loss of $3 million as of March 2025.

Overview:<BR>Sonnet BioTherapeutics Holdings, Inc. is an oncology-focused biotechnology company developing targeted biologic drugs with enhanced single or bispecific mechanisms, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 3.67 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.97 <BR>Return on Equity: -1,327.40% <BR>Price to Book: 3.67<BR><BR>Contact Details:<BR>Address: 100 Overlook Center, Suite 102, PRINCETON NJ: 08540 <BR>Tel: 1 609 3752227 <BR>Fax: 1 302 6451280 <BR>Website: http://www.chanticleerholdings.com/

Should I buy, sell or hold Sonnet BioTherapeutics Holdings, Inc.?

Who are in the management team of Sonnet BioTherapeutics Holdings, Inc.?

As of March 2022, the management team of Sonnet BioTherapeutics Holdings, Inc. is led by Dr. Pankaj Mohan, who is the Chairman, President, and CEO, alongside directors Mr. Nailesh Bhatt, Mr. Albert Dyrness, Mr. Donald Griffith, and Mr. Raghu Rao.

As of March 2022, the management team of Sonnet BioTherapeutics Holdings, Inc. includes Dr. Pankaj Mohan, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board of directors comprises Mr. Nailesh Bhatt, Mr. Albert Dyrness, Mr. Donald Griffith, and Mr. Raghu Rao, all of whom hold the designation of Director.

Is Sonnet BioTherapeutics Holdings, Inc. overvalued or undervalued?

As of February 13, 2025, Sonnet BioTherapeutics Holdings, Inc. is rated as risky and overvalued due to significant financial distress, reflected in its high price-to-book ratio of 3.96 and negative EV to EBIT and EV to EBITDA ratios, alongside a substantial annual loss of 85.84% compared to the S&P 500's 10.26% gain.

As of 13 February 2025, the valuation grade for Sonnet BioTherapeutics Holdings, Inc. has moved from does not qualify to risky. The company is currently considered overvalued based on its financial metrics. Notable ratios include a price to book value of 3.96, an EV to EBIT of -0.14, and an EV to EBITDA of -0.15, all indicating significant financial distress and lack of profitability.<BR><BR>In comparison to its peers, Sonnet BioTherapeutics shows a stark contrast; for instance, Theseus Pharmaceuticals, Inc. has a P/E of -3.1720 and an EV to EBITDA of 0.3754, while Vaxart, Inc. also carries a risky valuation with an EV to EBITDA of -1.9155. The company's substantial negative return over the past year of -85.84% compared to the S&P 500's 10.26% further underscores its overvaluation and the challenges it faces in the current market environment.

Is Sonnet BioTherapeutics Holdings, Inc. technically bullish or bearish?

As of September 12, 2025, Sonnet BioTherapeutics Holdings, Inc. shows a bullish technical trend with strong indicators, despite a bearish monthly Dow Theory, having outperformed the S&P 500 significantly in the short term but underperformed over the longer term.

As of 12 September 2025, the technical trend for Sonnet BioTherapeutics Holdings, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish with strong indicators supporting this view. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish. Daily moving averages also indicate a bullish trend. However, the monthly Dow Theory remains bearish, suggesting some caution. <BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 over the past week and month, with returns of 91.41% and 126.27% respectively, while it has underperformed over the longer term, particularly in the 1Y, 3Y, and 5Y periods.